Cohance Lifesciences to consider Q3 FY26 results on Feb 12, 2026; trading window closed
Cohance Lifesciences will hold a Board Meeting on February 12, 2026, to approve the Unaudited Financial Results for the quarter and nine-months ending December 31, 2025. The trading window will be closed from January 1, 2026, to February 14, 2026.
The announcement is material as it informs about the upcoming financial results release and the associated trading window closure, which affects insider trading activities.
The announcement is a routine intimation of a board meeting to approve financial results and a related trading window closure. It does not contain any new financial information or strategic changes.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced that a Meeting of the Board of Directors will be held on Thursday, February 12, 2026.
The primary purpose of this meeting is to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine-months ending December 31, 2025.
In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities will be closed from January 1, 2026, to February 14, 2026, inclusive.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.